Benzalin

Quick links to important sections

Benzalin

Treatment option: Zits, Acne Vulgaris

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Benzalin

Property Description
Active ingredient Clindamycin Phosphate, Benzoyl Peroxide
Form Topical Gel
Pharmacological class Topical Peroxide and Anti-infective Combination
General use Management of Acne Vulgaris
Origin Semi-synthetic (Clindamycin) and Synthetic (Benzoyl Peroxide)

The Clindamycin Phosphate and Benzoyl Peroxide combination is a prescription-only, Fixed-Dose Combination medication formulated as a Topical Gel for skin application. This preparation, chemically classified as a Topical Peroxide and Anti-infective Combination, is a recognized standard in the management of Acne Vulgaris. The product integrates two distinct active ingredients into a single formulation to provide a comprehensive approach. The Clindamycin Phosphate acts as an inactive prodrug, which reliably converts to the active Clindamycin upon contact with the skin, initiating the anti-infective process.

Active Ingredients, Form, and Chemical Origin

The combination features the semi-synthetic Lincosamide Antibiotic, Clindamycin (a derivative of Lincomycin), alongside the synthetic Antimicrobial/Keratolytic agent, Benzoyl Peroxide. This dual-component approach is clinically recognized for its efficacy against moderate inflammatory acne. Combination products containing Clindamycin and Benzoyl Peroxide are recognized for their role in reducing acne lesions.

The product is supplied as an aqueous/hydroalcoholic Gel, optimized for the topical route of administration. The addition of Benzoyl Peroxide to the antibiotic is a crucial feature intended for mitigating the risk of antibiotic resistance to the Clindamycin component.

General Therapeutic Purpose of the Dual Action

This dual-action gel is designed to achieve a more potent and stable therapeutic outcome than either ingredient used alone. The two ingredients work in concert: Clindamycin focuses on its bacteriostatic effect against Cutibacterium acnes bacteria, reducing microbial load and associated inflammation. Concurrently, Benzoyl Peroxide provides a strong Antimicrobial action and a Keratolytic effect to unplug follicular units. The overall aim is to comprehensively clear existing lesions and limit the formation of new acne outbreaks.

Regulatory References

  1. Topical Peroxide and Anti-infective Combination (WHO)
  2. mitigating the risk of antibiotic resistance

What side effects are possible with Benzalin?

Possible Side Effects and Safety Information

The safety profile for this topical gel, a fixed-dose combination of Clindamycin Phosphate and Benzoyl Peroxide, is characterized by both highly anticipated local skin reactions and regulatory warnings regarding potential systemic effects from the clindamycin component. All adverse reactions are classified and documented in official government regulatory texts.


Frequency-Classified Adverse Reactions

The most frequent adverse reactions are typically localized to the application site and follow standard regulatory frequency classifications:

Classification Examples of Reactions
Very Common (≥ 10%) Erythema (redness), dryness, peeling
Common (≥ 1% to < 10%) Burning sensation
Uncommon (≥ 0.1% to < 1%) Headache, sun sensitivity (photosensitivity)
Frequency Not Known Colitis, Anaphylaxis, Diarrhea, Abdominal Pain

Systemic and Population Safety Constraints

Serious Adverse Reactions: The regulatory labels include a mandatory focus on the potential for serious Gastrointestinal disorders, such as colitis (including pseudomembranous colitis), which is a rare but documented risk associated with systemic absorption of clindamycin. Serious allergic reactions, including anaphylaxis, are also listed under post-marketing reports.

Time-Related Safety Pattern: Local skin effects (erythema, peeling, dryness) are officially noted to be more frequently observed at the beginning of treatment and may subside with continued use.

Population-Specific Restrictions: The product is contraindicated in individuals with a history of Crohn's disease, ulcerative colitis, or prior antibiotic-associated colitis. Furthermore, safety and effectiveness have not been established in pediatric patients under 12 years of age.

Overall Safety Scope: The inclusion of Benzoyl Peroxide in the formulation addresses the primary long-term safety concern of developing antibiotic resistance to the Clindamycin component.

Overdose and Emergency Response

The official regulatory profile for Benzalin (Clindamycin Phosphate and Benzoyl Peroxide topical gel) outlines risks associated with both excessive topical use and the potential for systemic absorption of the active ingredients.

When to Seek Immediate Medical Help

The regulator mandates seeking emergency medical attention immediately if signs of a severe allergic reaction occur, such as swelling of the face, throat, or tongue, or difficulty breathing. Furthermore, the product must be discontinued immediately and a physician contacted at once if the patient develops significant, persistent, watery, or bloody diarrhea. These severe gastrointestinal symptoms are documented as potential indicators of antibiotic-associated colitis, which has been classified as a potentially life-threatening complication associated with clindamycin systemic absorption.

Overdose Manifestations and Management

Overexposure from excessive topical application is formally documented to result in severe local irritation, including pronounced redness (erythema), drying, peeling, and application site pain. For these local reactions, the officially described action is to reduce the frequency of use or temporarily interrupt treatment. Accidental ingestion requires immediately seeking medical advice or contacting a poison control center. Management for severe outcomes is generally symptomatic and supportive, involving measures like fluid replacement and diagnostic monitoring (e.g., specific stool assays). The regulatory labeling confirms that no specific antidote is documented for this formulation.

Therapeutic Uses of Benzalin

What Benzalin Treats: Main Uses and Benefits

Benzalin (benzocaine) is generally used in situations involving certain distressing symptoms to temporarily ease pain and discomfort on the surface of the body or mucous membranes. Its use is relevant in contexts marked by increased discomfort or tension, as it helps provide relief in a targeted area.

As a recognized local anesthetic, it is commonly used across conditions presenting with acute episodes of pain. It is commonly used to help with symptoms related to physical discomfort such as minor sunburn, burns, insect bites, or minor cuts and scrapes. It is also relevant for easing pain in the mouth or throat, for example, from canker sores or irritation. Its application is relevant in clinical contexts that involve acute or unstable symptom patterns where supportive symptomatic relief is appropriate.

In contexts where it is used, it contributes to improved comfort during periods of heightened symptoms by providing supportive relief when symptoms that interfere with daily functioning become noticeable. This supports the patient during difficult episodes by easing distress. A patient-oriented benefit is captured in the simple statement, “It helps improve day-to-day comfort during symptomatic periods.” It is considered relevant for the short-term management of discomfort across various conditions involving localized or surface pain.


Quick Fact: Relevant for Symptoms related to physical discomfort

Regulatory References

  1. NIH MedlinePlus states

Eligibility and Restrictions for Use

Who Can and Cannot Use Benzalin?

Eligibility for Clindamycin Phosphate and Benzoyl Peroxide Topical Gel is strictly defined by regulatory documents, focusing on patient history and age group. The medicine is primarily intended for adolescents and adults 12 years of age and older with acne vulgaris. Safety and effectiveness have not been established in pediatric patients under 12 years.


Absolute Contraindications

Use is strictly prohibited (contraindicated) for individuals with specific pre-existing conditions or sensitivities:

  • A known hypersensitivity to clindamycin, benzoyl peroxide, lincomycin, or any component of the formulation.
  • A history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis.

Restrictions and Special Considerations

Population Group Regulatory Status
Pregnancy Safety is not established. Use requires a physician's careful risk/benefit assessment.
Lactation Not recommended. Requires the physician to decide between discontinuing nursing or discontinuing the drug. Must not be applied to the breast area.
Atopic Patients Use with caution due to the potential for further skin drying.

These official statements define the population that is eligible or prohibited from using the medicine under labeled conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Benzalin (Clindamycin and Benzoyl Peroxide) has documented interactions with other medicines, primarily concerning topical co-administration, specific antibiotic incompatibilities, and a systemic interaction risk with certain agents used in surgery.

Documented Interaction Constraints

Official regulatory documents require restrictions on co-administration with the following:

Interacting Product Category Restriction / Regulatory Statement
Erythromycin Products Co-administration must be avoided due to in vitro evidence of antagonism with the clindamycin component.
Other Topical Acne Agents Use with caution due to the potential for a cumulative irritancy effect when used concomitantly with peeling, desquamating, or abrasive agents (e.g., Tretinoin).
Topical Dapsone Co-administration may result in a transient yellow or orange discoloration of the skin or facial hair.
Neuromuscular Blocking Agents Use with caution; the clindamycin component possesses neuromuscular blocking properties that may enhance the action of agents like Atracurium or Tubocurarine. Patients must inform providers before procedures requiring these agents.

Overall Interaction Profile

The product's official interaction structure is defined by the need to prevent antibiotic antagonism and localized skin irritation. A key warning involves the incompatibility with Erythromycin, which must not be co-administered. Additionally, caution is mandated when using the product alongside any other potentially irritating topical acne preparations. A critical systemic warning addresses the potential for the clindamycin component to potentiate muscle relaxation when patients are administered specific Neuromuscular Blocking Agents during surgical procedures.

Mechanism of Action

Dual-Action Microbial Load Control

This combination engages two distinct mechanisms to reduce the target bacterial population of Cutibacterium acnes. Clindamycin acts as an inhibitor, binding to the bacterial 50S ribosomal subunit to disrupt the peptidyl transferase reaction, thereby arresting the protein synthesis necessary for bacterial growth (a bacteriostatic effect). Simultaneously, Benzoyl Peroxide decomposes to release free oxygen radicals. These radicals non-specifically oxidize and denature key bacterial proteins, initiating a bactericidal effect. This multi-target action contributes to the reduction of microbial load, which subsequently attenuates the local inflammatory response mediated by bacterial antigens.

Follicular Pathway Modulation and Synergy

Benzoyl Peroxide also modulates the follicular keratinization pathway by exerting a keratolytic action. This mechanism causes the loosening and increased shedding of epithelial cells lining the hair follicle. This supports the unclogging of the sebaceous unit by preventing the buildup of trapped keratin and sebum. The concurrent use of BPO creates a critical mechanistic synergy; its non-specific oxidative mechanism reduces the biological pressure for C. acnes to develop ribosomal target modifications, thereby maintaining the activity of the primary inhibitory mechanism against the pressure of resistance.

Dosage and Administration Information

How to Use Benzalin (Clindamycin Phosphate and Benzoyl Peroxide Topical Gel)

This section explains the general principles and administration patterns for the combination topical gel.


Administration Scope

The route of administration for this fixed-dose combination product is topical application, exclusively for use on the skin. The gel is explicitly designated as not for oral, ophthalmic, or intravaginal use. The standard application frequency is once daily, typically occurring in the evening.


Labeled Dosing and Procedural Rules

The standard dosing schedule involves applying a "pea-sized amount" of the gel as a thin film over the entire affected area of the skin. Applying a larger quantity will not increase the medicine's effect but may heighten the risk of local skin irritation.

For preparation, the skin must be gently washed with a mild cleanser and patted dry before the gel is applied. Application must strictly avoid sensitive areas including the eyes, mouth, lips, and other mucous membranes. Hands should be thoroughly washed immediately after use.


Course Duration and Age Rules

Safety and effectiveness have not been evaluated for continuous use beyond 12 weeks; therefore, treatment courses should not typically exceed this duration. The product is indicated for use in patients 12 years of age and older, with safety not established for children younger than 12. The application pattern is also subject to environmental constraints, with instructions to minimize exposure to sunlight and artificial UV light during treatment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Benzalin

Research into the fixed-dose combination of Clindamycin Phosphate and Benzoyl Peroxide was studied for its use in Acne Vulgaris. The evidence base is structured primarily around clinical trials designed to understand how the two components work together and how the combination performs compared to its individual ingredients. This section summarizes the patterns observed in these studies, including areas where research is still developing.


Evidence for Use in Acne Vulgaris

The primary evidence comes from multiple large-scale short-term Randomized Controlled Trials (RCTs). The studies enrolled patient groups defined as having moderate-to-severe Acne Vulgaris. The populations typically included adolescents and adults aged 12 years and older.

Researchers explored several outcomes linked to inflammatory or irritative states. These included objective measures of skin status, such as standardized global assessments completed by investigators. The combination was compared using measures of both inflammatory and non-inflammatory lesion counts. Additionally, studies applied in studies examining patient-reported experiences, where tools were used in research exploring how symptoms change over time related to daily functioning and quality of life.

Comparative Studies Against Monotherapies

Research also included studies designed to compare the fixed combination against its two active components used separately (Clindamycin alone and Benzoyl Peroxide alone) and against vehicle control gels. The trials reported differences in the measured outcomes when the combination was compared to its monotherapy components. This type of comparative evidence contributes to the broader evidence landscape by helping to contextualize the combination product's performance.


Long-Term Data and Follow-Up Duration

Most pivotal trials establishing the use of this combination studies explored patient responses over a short-term follow-up duration, typically around 10 to 12 weeks. While this period research provides insight into short-term changes, the follow-up durations were limited. Therefore, the long-term effects are not fully established, and evidence that contributes to understanding symptom patterns over extended periods is limited.


What is Still Uncertain About the Research

The evidence has been broadly classified as High based on the quantity of controlled trial methodology. However, limitations exist that are relevant to a full understanding of the research landscape.

The comparative evidence is lacking in trials that directly compare this combination against all major competing combination therapies. Additionally, in some trials comparing the combination to the clindamycin-only component, potential for unblinding was observed in some studies due to the known physical characteristics of benzoyl peroxide. Finally, findings describe group patterns, not personal outcomes, and the research evidence highlights what is known — and what is still uncertain.

Frequently Asked Questions (FAQ)

Common questions about Benzalin (FAQ)


Q: Is Benzalin the same as other medicines for the same condition?

Benzalin is officially described as a fixed-dose combination product, meaning it contains two different active ingredients: the antibiotic clindamycin and the topical agent benzoyl peroxide. Regulatory sources indicate that this combination may help reduce the risk of the target bacteria developing resistance to the clindamycin component, compared to using the antibiotic ingredient alone.


Q: Can Benzalin cause weight gain or weight loss?

Weight changes are not listed among the frequently reported adverse reactions in the official regulatory documentation for this topical product.


Q: Is it common to feel tired when taking Benzalin?

Tiredness or fatigue is not listed among the commonly reported side effects in the official product information for Benzalin.


Q: What should I do if I experience mild stomach upset from Benzalin?

Official warnings primarily focus on the potential for serious gastrointestinal issues, such as colitis, linked to the clindamycin component. Regulatory warnings indicate that use should be discontinued and medical attention sought immediately if severe symptoms occur, such as bloody or prolonged diarrhea, or severe abdominal cramping. Mild, non-severe stomach upset is generally not specifically detailed within the official warnings concerning serious gastrointestinal risk.


Q: Are there any long-term effects associated with Benzalin use?

Official regulatory documents indicate that safety and effectiveness were evaluated for continuous use up to 12 weeks. Consequently, long-term effects beyond this period are not fully established based on the primary evidence. Additionally, some animal studies on one component suggest it can act as a tumor promoter, though the relevance of this finding to humans is unknown.


Q: What does the box warning or black box warning say about Benzalin, if applicable?

Benzalin does not carry a Black Box Warning, which is the most stringent safety warning required by the FDA. However, the official labeling does contain a prominent Warning regarding the potential for serious gastrointestinal issues, specifically colitis, associated with the clindamycin component. The warning indicates that use should be discontinued if a patient develops significant diarrhea.


Q: What research has been done on Benzalin's use in combination with other treatments?

Regulatory documents list specific restrictions on co-administration with other treatments. These documents specifically caution against using Benzalin with erythromycin products or other topical acne preparations that cause peeling or irritation. This is due to the potential for compounded skin irritation and concerns about antibiotic antagonism.


Q: Can Benzalin cause changes in blood pressure?

Changes in blood pressure are not listed among the commonly reported side effects in the official product's regulatory documentation.


Q: Why do doctors prescribe Benzalin over alternatives?

Official information describes Benzalin as combining the effects of an antibiotic (clindamycin) and an antimicrobial/keratolytic agent (benzoyl peroxide) in a single formulation. The dual action is documented as a way to address the primary components of acne and to help mitigate the risk of antibiotic resistance to the clindamycin component.


Q: How quickly does Benzalin usually start working?

Data from clinical studies show that reductions in inflammatory lesions have been observed as early as two weeks into the treatment course. However, the full effect studied in clinical trials is usually assessed after the treatment course duration, which is up to 12 weeks.


Q: What are the most commonly reported side effects of Benzalin?

According to regulatory documents, the most frequent adverse reactions are localized skin reactions classified as 'Very Common'. These reactions, seen in 10% or more of patients in clinical trials, most commonly include dryness, peeling (exfoliation), and redness (erythema) at the site of application.


Q: Is Benzalin safe to take if I am already taking supplements?

Official patient information indicates that a healthcare professional should be informed of all products being used. This includes prescription and nonprescription drugs, vitamins, nutritional supplements, and any herbal products.


Q: Does Benzalin contain sulfa or penicillin?

The active ingredients are clindamycin phosphate (a lincosamide antibiotic) and benzoyl peroxide. It does not contain penicillin or sulfa drugs. However, the product is contraindicated for individuals with a known allergy to clindamycin, benzoyl peroxide, or lincomycin.


Q: What happens if I forget to use Benzalin?

Official patient instructions describe applying the missed dose as soon as it is remembered, but skipping the dose and resuming the regular schedule if it is nearly time for the next application. Instructions indicate not to use extra product to compensate.


Q: Is Benzalin a controlled substance?

No, Benzalin (Clindamycin Phosphate and Benzoyl Peroxide Topical Gel) is not classified as a controlled substance by U.S. regulatory authorities.


Q: Can I use Benzalin if I have kidney problems?

While specific dose adjustments are typically not required for kidney impairment with this topical product, official patient information indicates that a healthcare professional should be informed of all existing medical conditions, including any history of kidney disease.


Q: Can I use Benzalin if I have liver problems?

Specific dose adjustments for liver impairment are generally not noted for this topical product. However, official information indicates that a complete medical history, including any history of liver disease, should be shared with a healthcare professional.


Q: Is Benzalin known to cause dizziness?

Dizziness has been reported as an adverse reaction in post-marketing experience with the product, meaning it was identified after initial clinical trials were completed. Its exact frequency is not reliably estimated.


Q: Can Benzalin make me more sensitive to the sun?

Yes, regulatory documents include a warning that one component, benzoyl peroxide, may increase sensitivity to sunlight (photosensitivity). Official instructions note that patients should minimize exposure to natural or artificial UV light, such as tanning beds or sun lamps, following application.


Q: Does Benzalin affect sleep patterns?

Changes in sleep patterns are not listed among the commonly reported side effects in the official product's regulatory documentation.


Q: What if Benzalin doesn't seem to be working for me?

Clinical trials generally demonstrate the intended benefit over a full treatment course, typically 10 to 12 weeks. If symptoms do not begin to improve or if they worsen during this time, official patient advice indicates that individuals should consult with a healthcare professional for an evaluation.


Q: Are there any specific laboratory tests required before or during Benzalin treatment?

The official product labeling for this topical gel does not mention any specific required laboratory tests for general use.


Q: Does Benzalin affect driving ability?

Official drug information from regulatory sources generally indicates that, given the way the product works and is applied, it is not expected to impair a patient's ability to drive or operate machinery.


Q: What are the common reasons people stop taking Benzalin?

While overall discontinuation rates are not explicitly provided, the most common adverse reactions that can lead to discontinuation are the localized skin effects. These include severe or persistent dryness, peeling, and redness at the application site.


Q: Are there known interactions between Benzalin and herbal remedies?

Official patient information indicates that a healthcare professional should be provided with a comprehensive list of all products being used, which includes herbal remedies. This is to ensure a complete understanding of potential interactions or effects.


Q: Does Benzalin affect my mood or mental clarity?

Effects on mood or mental clarity are not listed among the commonly reported side effects in the official product's regulatory documentation.


Q: Are there studies comparing Benzalin across different age groups?

The product is officially indicated for patients 12 years and older. Clinical studies have specifically included post-hoc analyses to examine the efficacy and safety profile of the product in adolescent subjects (aged 12 to less than 18 years).


Q: What are the official restrictions for using Benzalin?

Official restrictions define who can use the product and how it should be used. These include age limitations (not evaluated for use under 12 years), route of administration (topical use only), duration limits (safety not established beyond 12 continuous weeks), and specific medical conditions that strictly prohibit its use (such as a history of colitis).


Q: Is Benzalin a high-alert medication?

The term 'High-Alert Medication' is a classification often used by independent medication safety organizations, not a label directly applied by the FDA. The official FDA labeling itself focuses on specific warnings, such as the potential for colitis, that highlight important safety considerations.


Q: Is Benzalin manufactured by multiple companies?

Yes, as a fixed-dose combination product, the active ingredients are available under various brand names and in generic formulations, indicating that it is manufactured by multiple companies.

How should Benzalin be stored and disposed of?

How to Store and Dispose of BenzaClin Topical Gel

The storage and disposal instructions for BenzaClin Topical Gel (Clindamycin and Benzoyl Peroxide) are strictly defined by regulatory labeling to ensure product stability.


Storage Requirements

  • Unmixed Components: Must be stored in a refrigerator between 2 C to 8 C.
  • Mixed Gel (Dispensed Product): Must be stored at room temperature up to 25 C. The product must not be frozen.
  • Stability: The mixed gel is stable for 3 months (90 days). Any unused portion must be discarded after 3 months.
  • Protection: Keep the container tightly closed and away from excessive heat and moisture. The medication must be kept out of the sight and reach of children.

Disposal

Official disposal protocols require that unused or expired gel not be thrown into household trash or poured into wastewater (sinks or toilets). Patients should consult a pharmacist or use an authorized community drug take-back program for proper disposal of the unused product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Benzalin found in:

A-Z Index: